FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

Regulatory clearance adds a 1,400-mg subcutaneous CD38 antibody option using CirCLIQ on-body delivery or provider-administered injection, maintaining the same active medicine as the IV formulation.

Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...

Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeksMean weight loss with semaglutide 7.2 mg reached 21%, reflecting overall treatment efficacyUp to 84 ...

Glenmark Pharmaceuticals Inc., USA announce the launch of olanzapine for injection, 10 mg/vial, single-dose vial. Glenmark’s olanzapine for injection is bioequivalent and therapeutically equivalent to ...

IL-23 inhibitor lands indications for kids 6 years and up ...

As at-home healthcare continues to grow, ensuring sharps are consistently and properly disposed of will only become more ...

Phase III data supported setmelanotide's recent label expansion in acquired hypothalamic o ...

Anthropic’s AI-run espionage report shows why enterprises need stronger governance for AI agents, MCP connectors, and ...

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has ...

Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology ...

A chemotherapy ingredient that's in short supply in Canada can temporarily be imported and sold from a Chinese-authorized ...